NEW YORK – Genome editing startup Tome Biosciences will lay off 131 employees in November, according to a Worker Adjustment and Retraining Notice filed last week in Massachusetts.
The Watertown, Massachusetts-based therapeutics firm emerged from stealth in December 2023 and has raised $213 million between its Series A and B financing rounds.
Tome has licensed CRISPR-based genome editing technology from the Massachusetts Institute of Technology developed by Cofounders Omar Abudayyeh and Jonathan Gootenberg.
In January, Tome acquired Replace Therapeutics for $65 million in upfront and near-term milestones with a total deal value of up to $185 million of cash and stock.
Tome did not immediately respond to a request for comment.